Physician profile
John S Wells
NPI 1831359744
$2,719.60
in general payments reported to CMS, 2019-2025
33 companies · $676 in 2025
The $676 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $156 · 2021: $369 · 2022: $520 · 2023: $503 · 2024: $383 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.66 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $344.86 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $259.37 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Zimmer Biomet Holdings, INC. | $181.59 | 2022-2025 | Absorb |
| Corcept Therapeutics | $122.99 | 2024-2025 | Korlym |
| Novo Nordisk INC | $117.56 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $106.78 | 2019-2025 | |
| Astellas Pharma US INC | $101.98 | 2021-2024 | Veozah |
| Allergan, INC. | $90.44 | 2019-2021 | |
| Dexcom, INC. | $88.54 | 2021-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $84.04 | 2021-2025 | Freestyle Libre 3 |
| Janssen Biotech, INC. | $66.53 | 2024-2025 | Tremfya |
| Harmony Biosciences LLC | $65.45 | 2022-2024 | Wakix |
| Verona Pharma, INC. | $61.41 | 2025 | Ohtuvayre |
| Biohaven Pharmaceutical Holding Company LTD. | $48.59 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $47.78 | 2022-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.58 | 2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $39.91 | 2022-2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $38.84 | 2025 | Gvoke Hypopen |
| Medtronic, INC. | $38.38 | 2022-2024 | Minimed 780g |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.53 | 2023-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $33.99 | 2022 | |
| Tandem Diabetes Care, INC. | $26.86 | 2019-2022 | |
| Medtronic Minimed, INC. | $26.37 | 2019-2020 | |
| Lundbeck LLC | $20.46 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $16.95 | 2021 | |
| Vanda Pharmaceuticals INC. | $16.26 | 2024 | Fanapt |
| Glaxosmithkline, LLC. | $16.14 | 2020 | |
| Agios Pharmaceuticals, INC. | $16.05 | 2023 | Pyrukynd |
| Ultragenyx Pharmaceutical INC. | $15.35 | 2022 | |
| Ascensia Diabetes Care US INC. | $15.07 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.97 | 2020 | |
| Beta Bionics, INC. | $9.32 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.